Acumen Pharmaceuticals Inc (ABOS NASDAQ) stock market data APIs
$2.0338
0.08(3.9%)
as of October 17, 2025
Try our APIs with
free plan!
Acumen Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Prev. Close
2.0338
Open
2.1176
High
2.1563
Low
2.0199
52 wk Range
0.855-3.36
Market Cap
123 M
Shares Outstanding
60 573 K
Revenue
329 K
EPS
-0.68
Beta
0.201
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Acumen Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Acumen Pharmaceuticals Inc data using free add-ons & libraries
Get Acumen Pharmaceuticals Inc Fundamental Data
Acumen Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 329 K
- EBITDA: -143 920 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.51
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Acumen Pharmaceuticals Inc News
New
Relative Strength Alert For Pilgrims Pride
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a te...
Biotech Stocks Surge After Hours On Trial Updates And Strategic Moves
(RTTNews) - After-hours trading on Tuesday featured a wave of notable price moves across the biotech and therapeutics space, with several small- and mid-cap names posting sharp gains following clinica...
2 ‘Strong Buy’ Stocks That Wall Street Believes Can Soar 360% to 780%
Biotech stocks can offer significant upside because they have high-growth potential if their drug candidates succeed in trials or gain FDA approval. For long-term biotech investors who can accept the ...
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amylo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
